AACR PATIENT ADVOCATE FORUM

THE EVOLUTION OF FDA REGULATORY SCIENCE AND ITS IMPACT ON CANCER

Speakers

-in order of appearance

ALLISON ROSEN, MS
Patient Advocate, AACC Scientist↔Survivor Program®
Director, Project ECHO, American Cancer Society

Allison Rosen is a Houston, Texas native and colorectal cancer survivor. She dedicates her life to use her voice and platform to educate, advocate, and continuously learn how best to represent the collective colorectal cancer community.

Allison is Director of Project ECHO at the American Cancer Society, focusing on colorectal cancer prevention. She has a combined 16 years of experience in the oncology space, focusing on designing, implementing, and evaluating public health programs and initiatives to address cancer awareness and disparities among the medically underserved. She serves as a patient advocate working with Fight Colorectal Cancer, the National Coalition for Cancer Survivorship, the American Cancer Society Cancer Action Network, the Colorectal Cancer Alliance, the Colon Cancer Coalition, and SWOG Cancer Research Network and volunteers at MD Anderson Cancer Center. Through her own experience at beating stage II colorectal cancer, she works to bridge the gap between the healthcare system and the communities that it serves.

RICHARD PAZDUR, MD
Director, Oncology Center of Excellence
Food & Drug Administration

Richard Pazdur, M.D., is the director of the FDA’s Oncology Center of Excellence (OCE), established in 2017 to leverage the combined skills of FDA’s regulatory scientists and reviewers with expertise in drugs, biologics, and devices to expedite the development of novel cancer products. In this role, Dr. Pazdur is responsible for leading the effort to develop and execute an integrated regulatory approach to enhance the cross-center coordination of oncology product clinical review.

Dr. Pazdur joined the FDA in 1999 as director of the Division of Oncology Drug Products, in the Center for Drug Evaluation and Research. In 2005, he led the consolidation of divisions that reviewed drugs and therapeutic biologics for cancer and hematologic diseases into the Office of Hematology and Oncology Products (OHOP). In 2019, OHOP was reorganized to become the Office of Oncologic Diseases (OOD). Dr. Pazdur serves as acting director of OOD.
Prior to joining the FDA, Dr. Pazdur was professor of medicine at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. From 1988 to 1999, he held administrative positions of assistant vice president for academic affairs, associate director of clinical trials administration (Division of Medicine) and director of educational programs (Division of Medicine). From 1982 to 1988, he served on the faculty of Wayne State University, in Detroit, Michigan.

Dr. Pazdur received his bachelor’s degree from Northwestern University (Evanston, Illinois), his M.D. from Loyola Stritch School of Medicine (Maywood, Illinois), and completed clinical training at Rush-Presbyterian St. Luke’s Medical Center (Chicago, Illinois) and the University of Chicago Hospitals and Clinics.

DAVID R. PARKINSON, MD
President, Chief Executive Officer & Director
ESSA Pharma, Inc.

Dr. Parkinson has been ESSA’s President and Chief Executive Officer since 2016 and has been a member of ESSA’s Board of Directors since 2015. Dr. Parkinson has more than 30 years of experience in clinical oncology development.

Prior to joining ESSA, Dr. Parkinson was a Venture Partner at New Enterprise Associates, Inc. and served as the President and CEO of Nodality, Inc., a biotechnology company developing human cell-based translational diagnostic tools. Throughout his career, Dr. Parkinson has held senior roles in clinical oncology development at a number of pharmaceutical and biotech companies, including Biogen, Amgen and Novartis, and has overseen the successful clinical development of a series of cancer therapeutics, including Gleevec, Zometa, Femara, and Vectibix.

Dr. Parkinson currently serves as Director on the Boards of CTI Biopharma, Inc. and Angiocrine Bioscience Inc. Dr. Parkinson received his M.D. from the University of Toronto, has previously held academic positions at Tufts and the University of Texas MD Anderson Cancer Center, and has served as Chief of the Investigational Drug Branch and acting Associate Director of the Cancer Therapy Evaluation Program of the National Cancer Institute. He has authored over 100 peer-reviewed publications and is a recipient of the FDA’s Cody Medal.

KENNETH C. ANDERSON, MD, FAACR
Kraft Family Professor of Medicine, Harvard Medical School
Director, LeBow Institute for Myeloma Therapeutics and Jerome Multiple Myeloma Center, Dana-Farber Cancer Institute
Editor-in-Chief, Blood Cancer Discovery

Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and
American Cancer Society Clinical Research Professor. After graduating from Johns Hopkins Medical School, he trained in internal medicine at Johns Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute.

Over the last three decades, Dr. Anderson has focused his laboratory and clinical research studies on multiple myeloma. He has developed laboratory and animal models of the tumor in its microenvironment which allowed for both identification of novel targets and validation of novel targeted therapies, and then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome.

**Moderator**

**ANNA D. BARKER, PHD, FAACR**

Founder and Chair, AACR Scientist↔Survivor Program®
Chief Strategy Officer, Lawrence J. Ellison Institute for Transformative Medicine
Distinguished Visiting Fellow, Complex Adaptive Systems, Arizona State University

Dr. Barker is the founder and chair of the AACR Scientist↔Survivor Program® and chief strategy officer of the Lawrence J. Ellison Institute for Transformative Medicine and distinguished visiting fellow at Arizona State University. She develops information-based strategies through internal research and engagement of networks of leading experts in medicine, science, and engineering to solve complex problems in cancer and other diseases. Previously, Dr. Barker served as the principal deputy director of the National Cancer Institute (NCI) where she led the development of Foundational platforms (Clinical Proteomics and National Cancer Nanotechnology Centers) and national programs (e.g., TCGA, Physical-Sciences Oncology Centers) to support the emerging concept of precision medicine. Hallmarks of these strategic innovative programs were networks of global institutions, team science and publicly available data.

Post NCI, Dr. Barker served as director of Transformative Healthcare Networks, co-director of Complex Adaptive Systems -Biomedicine (CAS) and professor of practice, School of Life Sciences at Arizona State University (ASU), where she maintains a courtesy academic appointment. At ASU, she employed CAS approaches through “knowledge networks” to enable progress in areas ranging from clinical trial designs to biomarker discovery and applying concepts from the physical sciences to fundamentally understand and control complex diseases such as cancer.

Dr. Barker also spent several years at Battelle Memorial Institute, a nonprofit transdisciplinary research organization, where she progressed from a research scientist to serve in several senior executive roles. She has received numerous awards for her contributions to cancer research, cancer patients and patient advocates, professional organizations, and the ongoing national effort to prevent and cure cancer. Dr. Barker received her doctoral degree from the Ohio State University.